

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/R0EAD680CB6DEN.html>

Date: October 2022

Pages: 307

Price: US\$ 2,500.00 (Single User License)

ID: R0EAD680CB6DEN

Abstracts

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides an overview of the Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline landscape.

Respiratory syncytial virus (RSV) infection is a respiratory disease. It infects the lungs and breathing passages. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache and fever. Treatment includes proper medication and hygiene practice.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press

releases.

The Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Respiratory Syncytial Virus (RSV) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 9, 10, 17, 2, 76, 33 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 14, 12 and 6 molecules, respectively.

Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration

details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections (Infectious Disease) pipeline depth

and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Respiratory Syncytial Virus (RSV) Infections - Overview

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Respiratory Syncytial Virus (RSV) Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Respiratory Syncytial Virus (RSV) Infections - Companies Involved in Therapeutics Development

Respiratory Syncytial Virus (RSV) Infections - Drug Profiles

(human metapneumovirus + human respiratory syncytial virus) (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

(human parainfluenza virus [serotype 1] + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

(influenza (virus like particle) + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

(influenza + Coronavirus Disease 2019 (COVID-19) + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

(pertussis + respiratory syncytial virus) vaccine - Drug Profile

Product Description

Mechanism Of Action

ABX-196 - Drug Profile

Product Description

Mechanism Of Action

ADV-110 - Drug Profile

Product Description

Mechanism Of Action

AK-0529 - Drug Profile

Product Description

Mechanism Of Action

AK-0610 - Drug Profile

Product Description

Mechanism Of Action

AK-0611 - Drug Profile

Product Description

Mechanism Of Action

AK-0702 - Drug Profile

Product Description

Mechanism Of Action

ALVR-106 - Drug Profile

Product Description

Mechanism Of Action

Antisense RNAi Oligonucleotide for Respiratory Syncytial Virus (RSV) Infections - Drug Profile

Product Description

Mechanism Of Action

AR-201 - Drug Profile

Product Description

Mechanism Of Action

ASN-500 - Drug Profile

Product Description

Mechanism Of Action

AVG-388 - Drug Profile

Product Description

Mechanism Of Action

AZ-27 - Drug Profile

Product Description

Mechanism Of Action

B-1402 - Drug Profile

Product Description

Mechanism Of Action

BC-0005 - Drug Profile

Product Description
Mechanism Of Action
BC-0335 - Drug Profile
Product Description
Mechanism Of Action
BL-200 - Drug Profile
Product Description
Mechanism Of Action
BLB-201 - Drug Profile
Product Description
Mechanism Of Action
CAL-100 - Drug Profile
Product Description
Mechanism Of Action
CDX-RSV - Drug Profile
Product Description
Mechanism Of Action
clesrovimab - Drug Profile
Product Description
Mechanism Of Action
CR-32T - Drug Profile
Product Description
Mechanism Of Action
CT-02 - Drug Profile
Product Description
Mechanism Of Action
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
DPX-RSV - Drug Profile
Product Description
Mechanism Of Action
Drugs for Respiratory Syncytial Virus - Drug Profile
Product Description
Mechanism Of Action
Drugs for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
DSCav-1 - Drug Profile

Product Description
Mechanism Of Action
EDP-323 - Drug Profile
Product Description
Mechanism Of Action
EDP-938 - Drug Profile
Product Description
Mechanism Of Action
Fusion Proteins for Coronavirus Disease 2019 (COVID-19) and Respiratory Syncytial
Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
GSK-3844766A - Drug Profile
Product Description
Mechanism Of Action
GSK-3888550A - Drug Profile
Product Description
Mechanism Of Action
HEVS-124 - Drug Profile
Product Description
Mechanism Of Action
IB-004R - Drug Profile
Product Description
Mechanism Of Action
immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
IVX-121 - Drug Profile
Product Description
Mechanism Of Action
IVXA-12 - Drug Profile
Product Description
Mechanism Of Action
JNJ-64213175 - Drug Profile
Product Description
Mechanism Of Action

JNJ-64400141 - Drug Profile

Product Description

Mechanism Of Action

JNJ-7184 - Drug Profile

Product Description

Mechanism Of Action

JNJ-78991172 - Drug Profile

Product Description

Mechanism Of Action

JNJ-86051823 - Drug Profile

Product Description

Mechanism Of Action

MM-002 - Drug Profile

Product Description

Mechanism Of Action

MM-004 - Drug Profile

Product Description

Mechanism Of Action

molnupiravir - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibodies for Respiratory Syncytial Virus (RSV) Infections - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for Respiratory Syncytial Virus - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody for Respiratory Syncytial Virus Infections - Drug Profile

Product Description

Mechanism Of Action

Monoclonal Antibody to Inhibit RSV F Protein for Respiratory Syncytial Virus Infections -
Drug Profile

Product Description

Mechanism Of Action

MPE-8 - Drug Profile

Product Description

Mechanism Of Action

MPE-8 - Drug Profile

Product Description

Mechanism Of Action
MRIRSM-01 - Drug Profile
Product Description
Mechanism Of Action
MRKV-171 - Drug Profile
Product Description
Mechanism Of Action
mRNA-1230 - Drug Profile
Product Description
Mechanism Of Action
mRNA-1345 - Drug Profile
Product Description
Mechanism Of Action
mRNA-1365 - Drug Profile
Product Description
Mechanism Of Action
MV-012968 - Drug Profile
Product Description
Mechanism Of Action
MVA-BN RSV - Drug Profile
Product Description
Mechanism Of Action
Neumifil - Drug Profile
Product Description
Mechanism Of Action
nirsevimab - Drug Profile
Product Description
Mechanism Of Action
nitazoxanide CR - Drug Profile
Product Description
Mechanism Of Action
P-220241 - Drug Profile
Product Description
Mechanism Of Action
palivizumab biobetter - Drug Profile
Product Description
Mechanism Of Action
palivizumab biosimilar - Drug Profile
Product Description

Mechanism Of Action
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
palivizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
PF-06928316 - Drug Profile
Product Description
Mechanism Of Action
PF-07923567 - Drug Profile
Product Description
Mechanism Of Action
POLB-002 - Drug Profile
Product Description
Mechanism Of Action
Polysaccharides for Viral Infections - Drug Profile
Product Description
Mechanism Of Action
Product Candidates - Drug Profile
Product Description
Mechanism Of Action
Protein for Respiratory Syncytial Virus Infection - Drug Profile
Product Description
Mechanism Of Action
PRTX-007 - Drug Profile
Product Description
Mechanism Of Action
PSP-008 - Drug Profile
Product Description
Mechanism Of Action
ramatroban - Drug Profile
Product Description
Mechanism Of Action
RB-0026 - Drug Profile
Product Description

Mechanism Of Action
RBS-3149 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for Infectious Disease and Oncology - Drug Profile
Product Description
Mechanism Of Action
Recombinant Protein for RSV Infections - Drug Profile
Product Description
Mechanism Of Action
Recombinant Surfactant Associated Protein D Replacement for SARS and RSV
Infections - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particle) vaccines - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus (virus like particles) vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus [strain 98-25147-X] vaccine - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus [strain A/Maryland/001/11] vaccine - Drug Profile

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type a...

Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type a...

Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 3 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 3 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 4 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 5 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 6 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccine 7 - Drug Profile
Product Description
Mechanism Of Action
respiratory syncytial virus vaccines - Drug Profile
Product Description
Mechanism Of Action
REVTx-99 - Drug Profile

Product Description
Mechanism Of Action
rilematovir - Drug Profile
Product Description
Mechanism Of Action
RLS-0071 - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV - Drug Profile
Product Description
Mechanism Of Action
RSV Antivirals - Drug Profile
Product Description
Mechanism Of Action
RSV Artificial Intelligence Drug Discovery Program - Drug Profile
Product Description
Mechanism Of Action
RSV DFC - Drug Profile
Product Description
Mechanism Of Action
RSV Program - Drug Profile
Product Description
Mechanism Of Action
RSV Vaccine - Drug Profile
Product Description
Mechanism Of Action
RSV-276 - Drug Profile
Product Description
Mechanism Of Action
RSV-F005 - Drug Profile

Product Description
Mechanism Of Action
S-337395 - Drug Profile
Product Description
Mechanism Of Action
sisunatovir hydrochloride - Drug Profile
Product Description
Mechanism Of Action
Small Molecule 1 for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection - Drug Profile
Product Description
Mechanism Of Action
Small Molecules 2 for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Respiratory Syncytial Virus (RSV) Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules for Respiratory Syncytial Virus Infections - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Inhibit RSV F Protein for Respiratory Syncytial Virus Infection - Drug Profile
Product Description
Mechanism Of Action
SP-0125 - Drug Profile
Product Description
Mechanism Of Action
Syncytial Virus Fusion Inhibitor - Drug Profile
Product Description

Mechanism Of Action
TCB-029 - Drug Profile
Product Description
Mechanism Of Action
TD-214 - Drug Profile
Product Description
Mechanism Of Action
TE-4308 - Drug Profile
Product Description
Mechanism Of Action
TNM-001 - Drug Profile
Product Description
Mechanism Of Action
TP-0591816 - Drug Profile
Product Description
Mechanism Of Action
TRL-3D3 - Drug Profile
Product Description
Mechanism Of Action
TVB-3567 - Drug Profile
Product Description
Mechanism Of Action
TVX-004IP - Drug Profile
Product Description
Mechanism Of Action
verdinexor - Drug Profile
Product Description
Mechanism Of Action
VIS-RSV - Drug Profile
Product Description
Mechanism Of Action
VMT-3 - Drug Profile
Product Description
Mechanism Of Action
VMTX-002 - Drug Profile
Product Description
Mechanism Of Action
VN-0200 - Drug Profile
Product Description

Mechanism Of Action

VPI-251 - Drug Profile

Product Description

Mechanism Of Action

VXB-211 - Drug Profile

Product Description

Mechanism Of Action

VXX-005 - Drug Profile

Product Description

Mechanism Of Action

WLBU-2 - Drug Profile

Product Description

Mechanism Of Action

XW-001 - Drug Profile

Product Description

Mechanism Of Action

YH-009 - Drug Profile

Product Description

Mechanism Of Action

zapnometinib - Drug Profile

Product Description

Mechanism Of Action

zelpultide alfa - Drug Profile

Product Description

Mechanism Of Action

Respiratory Syncytial Virus (RSV) Infections - Dormant Projects

Respiratory Syncytial Virus (RSV) Infections - Discontinued Products

Respiratory Syncytial Virus (RSV) Infections - Product Development Milestones

Featured News & Press Releases

Oct 23, 2022: GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial

Oct 18, 2022: Enanta doses first participant in Phase I RSV treatment trial

Oct 07, 2022: Ark Biopharmaceutical presents positive results in phase 3 AIRFLO study of ziresovir in RSV-infected hospitalized infants at 12th International RSV Symposium

Oct 04, 2022: Enanta commences Phase IIb trial of RSV treatment

Oct 04, 2022: Icosavax initiates phase 1 trial of IVX-A12 against RSV and hMPV in older adults

Oct 02, 2022: Enanta Pharmaceuticals announces new preclinical data for its

respiratory virology programs to be presented at the 12th International RSV Symposium
Sep 29, 2022: Enanta Pharmaceuticals presents preclinical data for its respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) programs at the 12th International RSV Symposium

Sep 16, 2022: Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower respiratory tract disease in infants

Aug 26, 2022: Pfizer reports positive Phase III data for bivalent RSV vaccine in adults

Aug 12, 2022: NIHR and Sanofi announce first patient enrolled in large European clinical study to investigate protection against RSV, the leading cause of infant hospitalisation worldwide

Jul 22, 2022: Blue Lake enrolls first subject in Phase I RSV vaccine trial

Jun 28, 2022: Icosavax announces positive topline interim phase 1/1b results for VLP vaccine candidate IVX-121 against RSV

Jun 28, 2022: Bavarian Nordic announces grant of PRIME eligibility from the European Medicines Agency for its RSV vaccine candidate for the prevention of respiratory syncytial virus in older adults

Jun 24, 2022: Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by biomedical sciences researchers

Jun 13, 2022: GSK reports positive Phase III data for RSV vaccine in elderly

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Respiratory Syncytial Virus (RSV) Infections - Dormant Projects, 2022

Respiratory Syncytial Virus (RSV) Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Respiratory Syncytial Virus (RSV) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/R0EAD680CB6DEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R0EAD680CB6DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

